<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20241003181056&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20241003181056&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 03 Oct 2024 22:10:57 +0000</lastbuilddate>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Early-Career Interventionalists: Hope for the Future and Opportunity for Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):e241. doi: 10.1016/j.jacc.2024.07.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357949</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.039>10.1016/j.jacc.2024.07.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357949</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer A Rymer</dc:creator>
<dc:creator>Dennis I Narcisse</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Jacob A Doll</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Early-Career Interventionalists: Hope for the Future and Opportunity for Change</dc:title>
<dc:identifier>pmid:39357949</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.039</dc:identifier>
</item>
<item>
<title>Early-Career Interventionalists: Hope for the Future and Opportunity for Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):e239-e240. doi: 10.1016/j.jacc.2024.06.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357948</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.047>10.1016/j.jacc.2024.06.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357948</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jarrod D Frizzell</dc:creator>
<dc:creator>Lindsey Cilia</dc:creator>
<dc:creator>Kathryn L Dawson</dc:creator>
<dc:creator>Brett L Wanamaker</dc:creator>
<dc:creator>Rhian E Davies</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early-Career Interventionalists: Hope for the Future and Opportunity for Change</dc:title>
<dc:identifier>pmid:39357948</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.047</dc:identifier>
</item>
<item>
<title>Are Apolipoprotein A1 Infusions Effective Without LDL Cholesterol Control?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):e237. doi: 10.1016/j.jacc.2024.05.083.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357947</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.083>10.1016/j.jacc.2024.05.083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357947</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Francisco Blanco-Vaca</dc:creator>
<dc:creator>Joan Carles Escolà-Gil</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Are Apolipoprotein A1 Infusions Effective Without LDL Cholesterol Control?</dc:title>
<dc:identifier>pmid:39357947</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.083</dc:identifier>
</item>
<item>
<title>Reply: Patients With Cardiac Amyloidosis Are More Prone to Hypotension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357946/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):e235. doi: 10.1016/j.jacc.2024.07.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357946/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357946</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.040>10.1016/j.jacc.2024.07.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357946</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberto Foà</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Patients With Cardiac Amyloidosis Are More Prone to Hypotension</dc:title>
<dc:identifier>pmid:39357946</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.040</dc:identifier>
</item>
<item>
<title>Patients With Cardiac Amyloidosis Are More Prone to Hypotension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):e233. doi: 10.1016/j.jacc.2024.04.072.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357945</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.072>10.1016/j.jacc.2024.04.072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357945</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Shichu Liang</dc:creator>
<dc:creator>Ke Wan</dc:creator>
<dc:creator>Jialin Li</dc:creator>
<dc:creator>Jiaxin Chen</dc:creator>
<dc:creator>Yucheng Chen</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Patients With Cardiac Amyloidosis Are More Prone to Hypotension</dc:title>
<dc:identifier>pmid:39357945</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.072</dc:identifier>
</item>
<item>
<title>Hemodynamic Changes in Patients With Pectus Excavatum During Exercise: Relationship to Chest Wall Deformity Indexes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1498-1500. doi: 10.1016/j.jacc.2024.06.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357944</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.039>10.1016/j.jacc.2024.06.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357944</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Filaire</dc:creator>
<dc:creator>Frederic Costes</dc:creator>
<dc:creator>Julianne Touron</dc:creator>
<dc:creator>Marie M Tardy</dc:creator>
<dc:creator>Ioana Molnar</dc:creator>
<dc:creator>Hélène Perrault</dc:creator>
<dc:creator>Marc Filaire</dc:creator>
<dc:creator>Ruddy Richard</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hemodynamic Changes in Patients With Pectus Excavatum During Exercise: Relationship to Chest Wall Deformity Indexes</dc:title>
<dc:identifier>pmid:39357944</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.039</dc:identifier>
</item>
<item>
<title>Embracing Change: Human-Centered Cardiovascular Medicine in the Era of AI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357943/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1495-1497. doi: 10.1016/j.jacc.2024.08.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357943/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357943</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.047>10.1016/j.jacc.2024.08.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357943</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Seng Chan You</dc:creator>
<dc:creator>Xiaoxi Yao</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Embracing Change: Human-Centered Cardiovascular Medicine in the Era of AI</dc:title>
<dc:identifier>pmid:39357943</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.047</dc:identifier>
</item>
<item>
<title>The Legend of John Henry and the Role of Artificial Intelligence in the Destruction of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1492-1494. doi: 10.1016/j.jacc.2024.07.041.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357942</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.041>10.1016/j.jacc.2024.07.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357942</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Legend of John Henry and the Role of Artificial Intelligence in the Destruction of Cardiology</dc:title>
<dc:identifier>pmid:39357942</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.041</dc:identifier>
</item>
<item>
<title>Contemporary Training in American Critical Care Cardiology: Minnesota Critical Care Cardiology Education Summit: JACC Scientific Expert Panel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>This consensus statement emerges from collaborative efforts among leading figures in critical care cardiology throughout the United States, who met to share their collective expertise on issues faced by those active in or pursuing contemporary critical care cardiology education. The panel applied fundamentals of adult education and curriculum design, reviewed requisite training necessary to provide high-quality care to critically ill patients with cardiac pathology, and devoted attention to a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1436-1454. doi: 10.1016/j.jacc.2024.05.082.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This consensus statement emerges from collaborative efforts among leading figures in critical care cardiology throughout the United States, who met to share their collective expertise on issues faced by those active in or pursuing contemporary critical care cardiology education. The panel applied fundamentals of adult education and curriculum design, reviewed requisite training necessary to provide high-quality care to critically ill patients with cardiac pathology, and devoted attention to a purposeful approach emphasizing diversity, equity, and inclusion in developing this nascent field. The resulting paper offers a comprehensive guide for current trainees, with insights about the present landscape of critical care cardiology while highlighting issues that need to be addressed for continued advancement. By delineating future directions with careful consideration and intentionality, this Expert Panel aims to facilitate the continued growth and maturation of critical care cardiology education and practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357941</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.082>10.1016/j.jacc.2024.05.082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357941</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea M Elliott</dc:creator>
<dc:creator>Jason A Bartos</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>P Elliott Miller</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Carlos Alviar</dc:creator>
<dc:creator>Courtney Bennett</dc:creator>
<dc:creator>David D Berg</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Meshe Chonde</dc:creator>
<dc:creator>Garima Dahiya</dc:creator>
<dc:creator>Jessica Fleitman</dc:creator>
<dc:creator>Ann Gage</dc:creator>
<dc:creator>Barinder S Hansra</dc:creator>
<dc:creator>Andrew Higgins</dc:creator>
<dc:creator>Steven M Hollenberg</dc:creator>
<dc:creator>James M Horowitz</dc:creator>
<dc:creator>Jacob C Jentzer</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Yoav Karpenshif</dc:creator>
<dc:creator>Ran Lee</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Thomas S Metkus</dc:creator>
<dc:creator>Srini Mukundan</dc:creator>
<dc:creator>Zachary J Rhinehart</dc:creator>
<dc:creator>Balimkiz Senman</dc:creator>
<dc:creator>Mourad Senussi</dc:creator>
<dc:creator>Michael Solomon</dc:creator>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:creator>David M Dudzinski</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Contemporary Training in American Critical Care Cardiology: Minnesota Critical Care Cardiology Education Summit: JACC Scientific Expert Panel</dc:title>
<dc:identifier>pmid:39357941</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.082</dc:identifier>
</item>
<item>
<title>Closing PFOs to Prevent Stroke: A False Sense of Security</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357940/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1434-1435. doi: 10.1016/j.jacc.2024.08.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357940/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357940</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.045>10.1016/j.jacc.2024.08.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357940</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pooja Khatri</dc:creator>
<dc:creator>Pooneh Nabavizadeh</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Closing PFOs to Prevent Stroke: A False Sense of Security</dc:title>
<dc:identifier>pmid:39357940</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.045</dc:identifier>
</item>
<item>
<title>Risk of Ischemic Stroke After Patent Foramen Ovale Closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357939/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The 4-year risk of ischemic stroke after routine PFO closure for cryptogenic stroke was comparable to that observed in clinical trials, but remained higher than in the general population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1424-1433. doi: 10.1016/j.jacc.2024.07.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transcatheter patent foramen ovale (PFO) closure is the recommended treatment for patients age 18 to 60 years with cryptogenic stroke having a high probability of being PFO-related. Limited data exist on stroke recurrence after PFO closure outside clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to examine stroke recurrence after PFO closure in routine clinical practice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used nationwide population-based Danish registries to conduct a cohort study of all patients with PFO closure during 2008 to 2021 (n = 1,162) and a birth year and sex-matched comparison cohort from the general population (n = 11,620). We calculated absolute and relative risks of ischemic stroke within 4 years after PFO closure. We used weighted Cox regression to estimate adjusted HRs of the association between PFO closure vs the general population and ischemic stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The absolute risks of ischemic stroke in patients with PFO closure and in the general population, respectively, were 1.4% (95% CI: 0.8%-2.3%) and 0.1% (95% CI: 0.0%-0.1%) at 1 year, 1.4% (95% CI: 0.8%-2.3%) and 0.2% (95% CI: 0.2%-0.4%) at 2 years, 2.2% (95% CI: 1.3%-3.5%) and 0.4% (95% CI: 0.2%-0.5%) at 3 years, and 2.5% (95% CI: 1.5%-4.0%) and 0.4% (95% CI: 0.3%-0.6%) at 4 years. Thus, the absolute 4-year risk of ischemic stroke was 2.1% (95% CI: 0.9%-3.3%) higher in patients with PFO closure than in the general population, corresponding to an adjusted HR of 6.3 (95% CI: 3.1-12.6).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 4-year risk of ischemic stroke after routine PFO closure for cryptogenic stroke was comparable to that observed in clinical trials, but remained higher than in the general population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357939/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357939</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.015>10.1016/j.jacc.2024.07.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357939</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Kasper Bonnesen</dc:creator>
<dc:creator>Kasper Korsholm</dc:creator>
<dc:creator>Asger Andersen</dc:creator>
<dc:creator>Lars Pedersen</dc:creator>
<dc:creator>Claus Ziegler Simonsen</dc:creator>
<dc:creator>Jens Erik Nielsen-Kudsk</dc:creator>
<dc:creator>Morten Schmidt</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Ischemic Stroke After Patent Foramen Ovale Closure</dc:title>
<dc:identifier>pmid:39357939</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.015</dc:identifier>
</item>
<item>
<title>Seeing Is Knowing: Noninvasive Imaging Outperforms Traditional Risk Assessment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1404-1406. doi: 10.1016/j.jacc.2024.06.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357938</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.048>10.1016/j.jacc.2024.06.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357938</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Seeing Is Knowing: Noninvasive Imaging Outperforms Traditional Risk Assessment</dc:title>
<dc:identifier>pmid:39357938</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.048</dc:identifier>
</item>
<item>
<title>Influence of Subclinical Atherosclerosis Burden and Progression on Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1391-1403. doi: 10.1016/j.jacc.2024.06.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P &lt; 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm<sup>3</sup>. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm<sup>3</sup> change; P = 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357937</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.045>10.1016/j.jacc.2024.06.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357937</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Ana García-Álvarez</dc:creator>
<dc:creator>Ana Devesa</dc:creator>
<dc:creator>Virginia Mass</dc:creator>
<dc:creator>Ruth Owen</dc:creator>
<dc:creator>Antonio Quesada</dc:creator>
<dc:creator>José J Fuster</dc:creator>
<dc:creator>Inés García-Lunar</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Javier Sánchez-González</dc:creator>
<dc:creator>Samantha Sartori</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Vicente Andres</dc:creator>
<dc:creator>Pieter Muntendam</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Influence of Subclinical Atherosclerosis Burden and Progression on Mortality</dc:title>
<dc:identifier>pmid:39357937</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.045</dc:identifier>
</item>
<item>
<title>Leveraging Diagnostic Criteria to Inform Prognosis in Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357936/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1388-1390. doi: 10.1016/j.jacc.2024.08.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357936/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357936</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.003>10.1016/j.jacc.2024.08.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357936</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Garrick C Stewart</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Leveraging Diagnostic Criteria to Inform Prognosis in Myocarditis</dc:title>
<dc:identifier>pmid:39357936</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.003</dc:identifier>
</item>
<item>
<title>Prognostic Implications of Clinical and Imaging Diagnostic Criteria for Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a real-world cohort of patients with possible myocarditis, diagnosis was reached in most patients using ESC criteria whereas only approximately one-quarter of patients reached a diagnosis with LLC. The independent prognostic value of ESC-criteria and LLC highlights the complementary role of clinical and CMR-based findings in the diagnosis and risk stratification of myocarditis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8;84(15):1373-1387. doi: 10.1016/j.jacc.2024.07.018.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The European Society of Cardiology (ESC), the American College of Cardiology, the American Heart Association, and expert consensus documents provide different diagnostic criteria for myocarditis. Their overlap and prognostic value have never been compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to assess and compare the predictive value of ESC criteria for clinically suspected myocarditis, updated Lake-Louise criteria (LLC), American Heart Association criteria for probable acute myocarditis (pAM), and expert consensus criteria for acute myocarditis (AM) and complicated myocarditis (CM).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with a clinical suspicion of myocarditis referred for cardiac magnetic resonance were enrolled at 2 centers. Those with any prior cardiomyopathy were excluded. The association of composite outcome events (heart failure hospitalization, recurrent myocarditis, sustained ventricular tachycardia, or death) with ESC diagnostic criteria, LLC, pAM, AM, and CM were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1,557 consecutive patients referred for cardiac magnetic resonance with possible myocarditis, 1,050 (62.6% male; 48.9 ± 16.8 years of age) were without an alternative diagnosis. Of those, 938 (89.3%) met ESC criteria for clinically suspected myocarditis, 299 (28.5%) LLC, and 356 (33.9%), 216 (20.6%), and 77 (7.3%) pAM, AM, and CM, respectively. Adverse events occurred in 161 patients (15.3%) during a median follow-up of 3.4 years. The highest annualized event rates (6.6%) were observed in patients meeting LLC, whereas negative ESC criteria indicated excellent prognosis (0.7% annualized event rate). Among all myocarditis definitions, ESC criteria and LLC were the strongest multivariable outcome predictors and had independent and incremental prognostic value (HR<sub>adjusted</sub>: 3.87; 95% CI: 1.22-12.2; P = 0.021, and HR<sub>adjusted</sub>: 2.53; 95% CI: 1.83-3.49; P &lt; 0.001, respectively) when adjusted for clinical characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a real-world cohort of patients with possible myocarditis, diagnosis was reached in most patients using ESC criteria whereas only approximately one-quarter of patients reached a diagnosis with LLC. The independent prognostic value of ESC-criteria and LLC highlights the complementary role of clinical and CMR-based findings in the diagnosis and risk stratification of myocarditis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357935</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.018>10.1016/j.jacc.2024.07.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357935</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Benedikt Bernhard</dc:creator>
<dc:creator>Martin E Marxer</dc:creator>
<dc:creator>Jan C Zurkirchen</dc:creator>
<dc:creator>Jonathan Schütze</dc:creator>
<dc:creator>Andreas Wahl</dc:creator>
<dc:creator>Elena Elchinova</dc:creator>
<dc:creator>Giancarlo Spano</dc:creator>
<dc:creator>Martina Boscolo Berto</dc:creator>
<dc:creator>Monika Wieser</dc:creator>
<dc:creator>Chrysoula Garefa</dc:creator>
<dc:creator>Moritz Hundertmark</dc:creator>
<dc:creator>Maryam Pavlicek-Bahlo</dc:creator>
<dc:creator>Isaac Shiri</dc:creator>
<dc:creator>Raymond Y Kwong</dc:creator>
<dc:creator>Christoph Gräni</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Implications of Clinical and Imaging Diagnostic Criteria for Myocarditis</dc:title>
<dc:identifier>pmid:39357935</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.018</dc:identifier>
</item>
<item>
<title>The TMEM132B-GABA&lt;sub>;A&lt;/sub>; receptor complex controls alcohol actions in the brain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357522/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>Alcohol is the most consumed and abused psychoactive drug globally, but the molecular mechanisms driving alcohol action and its associated behaviors in the brain remain enigmatic. Here, we have discovered a transmembrane protein TMEM132B that is a GABA(A) receptor (GABA(A)R) auxiliary subunit. Functionally, TMEM132B promotes GABA(A)R expression at the cell surface, slows receptor deactivation, and enhances the allosteric effects of alcohol on the receptor. In TMEM132B knockout (KO) mice or...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 27:S0092-8674(24)01024-9. doi: 10.1016/j.cell.2024.09.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alcohol is the most consumed and abused psychoactive drug globally, but the molecular mechanisms driving alcohol action and its associated behaviors in the brain remain enigmatic. Here, we have discovered a transmembrane protein TMEM132B that is a GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) auxiliary subunit. Functionally, TMEM132B promotes GABA<sub>A</sub>R expression at the cell surface, slows receptor deactivation, and enhances the allosteric effects of alcohol on the receptor. In TMEM132B knockout (KO) mice or TMEM132B I499A knockin (KI) mice in which the TMEM132B-GABA<sub>A</sub>R interaction is specifically abolished, GABAergic transmission is decreased and alcohol-induced potentiation of GABA<sub>A</sub>R-mediated currents is diminished in hippocampal neurons. Behaviorally, the anxiolytic and sedative/hypnotic effects of alcohol are markedly reduced, and compulsive, binge-like alcohol consumption is significantly increased. Taken together, these data reveal a GABA<sub>A</sub>R auxiliary subunit, identify the TMEM132B-GABA<sub>A</sub>R complex as a major alcohol target in the brain, and provide mechanistic insights into alcohol-related behaviors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357522/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357522</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.006>10.1016/j.cell.2024.09.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357522</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Guohao Wang</dc:creator>
<dc:creator>Shixiao Peng</dc:creator>
<dc:creator>Miriam Reyes Mendez</dc:creator>
<dc:creator>Angelo Keramidas</dc:creator>
<dc:creator>David Castellano</dc:creator>
<dc:creator>Kunwei Wu</dc:creator>
<dc:creator>Wenyan Han</dc:creator>
<dc:creator>Qingjun Tian</dc:creator>
<dc:creator>Lijin Dong</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Wei Lu</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The TMEM132B-GABA&lt;sub>;A&lt;/sub>; receptor complex controls alcohol actions in the brain</dc:title>
<dc:identifier>pmid:39357522</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.006</dc:identifier>
</item>
<item>
<title>Diatom pyrenoids are encased in a protein shell that enables efficient CO&lt;sub>;2&lt;/sub>; fixation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357521/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>Pyrenoids are subcompartments of algal chloroplasts that increase the efficiency of Rubisco-driven CO(2) fixation. Diatoms fix up to 20% of global CO(2), but their pyrenoids remain poorly characterized. Here, we used in vivo photo-crosslinking to identify pyrenoid shell (PyShell) proteins, which we localized to the pyrenoid periphery of model pennate and centric diatoms, Phaeodactylum tricornutum and Thalassiosira pseudonana. In situ cryo-electron tomography revealed that pyrenoids of both...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 27:S0092-8674(24)01031-6. doi: 10.1016/j.cell.2024.09.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pyrenoids are subcompartments of algal chloroplasts that increase the efficiency of Rubisco-driven CO<sub>2</sub> fixation. Diatoms fix up to 20% of global CO<sub>2</sub>, but their pyrenoids remain poorly characterized. Here, we used in vivo photo-crosslinking to identify pyrenoid shell (PyShell) proteins, which we localized to the pyrenoid periphery of model pennate and centric diatoms, Phaeodactylum tricornutum and Thalassiosira pseudonana. In situ cryo-electron tomography revealed that pyrenoids of both diatom species are encased in a lattice-like protein sheath. Single-particle cryo-EM yielded a 2.4-Å-resolution structure of an in vitro TpPyShell1 lattice, which showed how protein subunits interlock. T. pseudonana TpPyShell1/2 knockout mutants had no PyShell sheath, altered pyrenoid morphology, and a high-CO<sub>2</sub> requiring phenotype, with reduced photosynthetic efficiency and impaired growth under standard atmospheric conditions. The structure and function of the diatom PyShell provide a molecular view of how CO<sub>2</sub> is assimilated in the ocean, a critical ecosystem undergoing rapid change.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357521/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357521</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.013>10.1016/j.cell.2024.09.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357521</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ginga Shimakawa</dc:creator>
<dc:creator>Manon Demulder</dc:creator>
<dc:creator>Serena Flori</dc:creator>
<dc:creator>Akihiro Kawamoto</dc:creator>
<dc:creator>Yoshinori Tsuji</dc:creator>
<dc:creator>Hermanus Nawaly</dc:creator>
<dc:creator>Atsuko Tanaka</dc:creator>
<dc:creator>Rei Tohda</dc:creator>
<dc:creator>Tadayoshi Ota</dc:creator>
<dc:creator>Hiroaki Matsui</dc:creator>
<dc:creator>Natsumi Morishima</dc:creator>
<dc:creator>Ryosuke Okubo</dc:creator>
<dc:creator>Wojciech Wietrzynski</dc:creator>
<dc:creator>Lorenz Lamm</dc:creator>
<dc:creator>Ricardo D Righetto</dc:creator>
<dc:creator>Clarisse Uwizeye</dc:creator>
<dc:creator>Benoit Gallet</dc:creator>
<dc:creator>Pierre-Henri Jouneau</dc:creator>
<dc:creator>Christoph Gerle</dc:creator>
<dc:creator>Genji Kurisu</dc:creator>
<dc:creator>Giovanni Finazzi</dc:creator>
<dc:creator>Benjamin D Engel</dc:creator>
<dc:creator>Yusuke Matsuda</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Diatom pyrenoids are encased in a protein shell that enables efficient CO&lt;sub>;2&lt;/sub>; fixation</dc:title>
<dc:identifier>pmid:39357521</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.013</dc:identifier>
</item>
<item>
<title>Molecular basis of global promoter sensing and nucleosome capture by the SWR1 chromatin remodeler</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39357520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>The SWR1 chromatin remodeling complex is recruited to +1 nucleosomes downstream of transcription start sites of eukaryotic promoters, where it exchanges histone H2A for the specialized variant H2A.Z. Here, we use cryoelectron microscopy (cryo-EM) to resolve the structural basis of the SWR1 interaction with free DNA, revealing a distinct open conformation of the Swr1 ATPase that enables sliding from accessible DNA to nucleosomes. A complete structural model of the SWR1-nucleosome complex...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 27:S0092-8674(24)01025-0. doi: 10.1016/j.cell.2024.09.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The SWR1 chromatin remodeling complex is recruited to +1 nucleosomes downstream of transcription start sites of eukaryotic promoters, where it exchanges histone H2A for the specialized variant H2A.Z. Here, we use cryoelectron microscopy (cryo-EM) to resolve the structural basis of the SWR1 interaction with free DNA, revealing a distinct open conformation of the Swr1 ATPase that enables sliding from accessible DNA to nucleosomes. A complete structural model of the SWR1-nucleosome complex illustrates critical roles for Swc2 and Swc3 subunits in oriented nucleosome engagement by SWR1. Moreover, an extended DNA-binding α helix within the Swc3 subunit enables sensing of nucleosome linker length and is essential for SWR1-promoter-specific recruitment and activity. The previously unresolved N-SWR1 subcomplex forms a flexible extended structure, enabling multivalent recognition of acetylated histone tails by reader domains to further direct SWR1 toward the +1 nucleosome. Altogether, our findings provide a generalizable mechanism for promoter-specific targeting of chromatin and transcription complexes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39357520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39357520</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.007>10.1016/j.cell.2024.09.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39357520</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert K Louder</dc:creator>
<dc:creator>Giho Park</dc:creator>
<dc:creator>Ziyang Ye</dc:creator>
<dc:creator>Justin S Cha</dc:creator>
<dc:creator>Anne M Gardner</dc:creator>
<dc:creator>Qin Lei</dc:creator>
<dc:creator>Anand Ranjan</dc:creator>
<dc:creator>Eva Höllmüller</dc:creator>
<dc:creator>Florian Stengel</dc:creator>
<dc:creator>B Franklin Pugh</dc:creator>
<dc:creator>Carl Wu</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of global promoter sensing and nucleosome capture by the SWR1 chromatin remodeler</dc:title>
<dc:identifier>pmid:39357520</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.007</dc:identifier>
</item>
<item>
<title>Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In patients with chronic Chagas cardiomyopathy at moderate to high risk of mortality, ICD did not reduce the risk of all-cause mortality. However, ICD significantly reduced the risk of SCD, pacing need, and heart failure hospitalization compared with amiodarone therapy. Further studies are warranted to confirm the evidence generated by this trial.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3169. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that ICD is more effective than amiodarone therapy for primary prevention of all-cause mortality in patients with chronic Chagas cardiomyopathy and moderate to high mortality risk, assessed by the Rassi score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: CHAGASICS is an open-label, randomized clinical trial. The study enrolled patients from 13 centers in Brazil from May 30, 2014, to August 13, 2021, with the last follow-up November 8, 2021. Patients with serological findings positive for Chagas disease, a Rassi risk score of at least 10 points (intermediate to high risk), and at least 1 episode of nonsustained ventricular tachycardia were eligible to participate. Data were analyzed from May 3, 2022, to June 16, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 1:1 to receive ICD or amiodarone (with a loading dose of 600 mg after randomization).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, and secondary outcomes included SCD, hospitalization for heart failure, and necessity of a pacemaker during the entire follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study was stopped prematurely for administrative reasons, with 323 patients randomized (166 in the amiodarone group and 157 in the ICD group), rather than the intended 1100 patients. Analysis was by intention to treat at a median follow-up of 3.6 (IQR, 1.8-4.4) years. Mean (SD) age was 57.4 (9.8) years, 185 patients (57.3%) were male, and the mean (SD) left ventricular ejection fraction was 37.0% (11.6%). There were 60 deaths (38.2%) in the ICD arm and 64 (38.6%) in the amiodarone group (hazard ratio [HR], 0.86 [95% CI, 0.60-1.22]; P = .40). The rates of SCD (6 [3.8%] vs 23 [13.9%]; HR, 0.25 [95% CI, 0.10-0.61]; P = .001), bradycardia requiring pacing (3 [1.9%] vs 27 [16.3%]; HR, 0.10 [95% CI, 0.03-0.34]; P &lt; .001), and heart failure hospitalization (14 [8.9%] vs 28 [16.9%]; HR, 0.46 [95% CI, 0.24-0.87]; P = .01) were lower in the ICD group compared with the amiodarone arm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with chronic Chagas cardiomyopathy at moderate to high risk of mortality, ICD did not reduce the risk of all-cause mortality. However, ICD significantly reduced the risk of SCD, pacing need, and heart failure hospitalization compared with amiodarone therapy. Further studies are warranted to confirm the evidence generated by this trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01722942.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39356542</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3169>10.1001/jamacardio.2024.3169</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356542</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Martino Martinelli-Filho</dc:creator>
<dc:creator>José A Marin-Neto</dc:creator>
<dc:creator>Mauricio Ibrahim Scanavacca</dc:creator>
<dc:creator>Angelo Amato Vincenzo de Paola</dc:creator>
<dc:creator>Paulo de Tarso Jorge Medeiros</dc:creator>
<dc:creator>Ruth Owen</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Sergio Freitas de Siqueira</dc:creator>
<dc:creator>CHAGASICS investigators</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39356542</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3169</dc:identifier>
</item>
<item>
<title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39356539</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3020>10.1001/jamacardio.2024.3020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356539</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:creator>Andrea Erriquez</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk-Reply</dc:title>
<dc:identifier>pmid:39356539</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3020</dc:identifier>
</item>
<item>
<title>Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241003181056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.2612. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Greater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: SAVM vs sham control procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, -0.03 mm Hg; 95% CI, -2.5 to 2.5 mm Hg; P = .95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, -6.1% to 15.4%; P = .36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, -9.2% to 18.8%; P = .48).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04592445.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241003181056&v=2.18.0.post9+e462414">39356530</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2612>10.1001/jamacardio.2024.2612</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356530</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Rajeev C Mohan</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Peter Fail</dc:creator>
<dc:creator>Parag Goyal</dc:creator>
<dc:creator>Scott L Hummel</dc:creator>
<dc:creator>Teona Zirakashvili</dc:creator>
<dc:creator>Tamaz Shaburishvili</dc:creator>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Christopher D Nielsen</dc:creator>
<dc:creator>Stanley J Chetcuti</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Rajiv Gulati</dc:creator>
<dc:creator>Luke Kim</dc:creator>
<dc:creator>Keith Benzuly</dc:creator>
<dc:creator>Sumeet S Mitter</dc:creator>
<dc:creator>Liviu Klein</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Ralph S Augostini</dc:creator>
<dc:creator>John E Blair</dc:creator>
<dc:creator>Krishna Rocha-Singh</dc:creator>
<dc:creator>Daniel Burkhoff</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Sami I Somo</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39356530</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2612</dc:identifier>
</item>





























</channel>
</rss>